Literature DB >> 31995408

Respiratory syncytial virus infection: why does disease severity vary among individuals?

Alireza Tahamtan1,2, Saeed Samadizadeh2, Mostafa Rastegar2, Britt Nakstad3, Vahid Salimi4.   

Abstract

Introduction: Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract infections in infancy. While many infants are infected with RSV, the nature and severity of the disease vary among individuals. RSV causes bronchiolitis, pneumonia, and asthma exacerbation. However, most children infected with RSV have only mild upper airways disease and may be asymptomatic.Areas covered: Despite efforts to elucidate mechanisms for the various clinical responses to RSV infection, they remain largely unknown, suggesting that susceptibility and disease are influenced by multiple intrinsic and extrinsic factors. This article reviews the available literature on the field of RSV disease severity and discusses important factors associated to susceptibility and different disease outcome.Expert opinion: The severity of RSV-induced illness is a phenomenon that depends on a variety of graded mechanisms of interaction between the host, virus, and environment. This may lead to differences in the intensity of immune response in the lung and different courses of the disease. By characterizing, classifying, and grading the affecting factors in high-risk patients versus those who do not fall ill by RSV, we may find therapies or point to disease-limiting medications.

Entities:  

Keywords:  Disease severity; RSV; environment; genetic background; risk factor; virus genotype

Mesh:

Year:  2020        PMID: 31995408     DOI: 10.1080/17476348.2020.1724095

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  9 in total

1.  Induced Pluripotent Stem Cell Derived Human Lung Organoids to Map and Treat the SARS-CoV2 Infections In Vitro.

Authors:  Saketh Kapoor; Muhammad Nihad; Bipasha Bose
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Maternal RSV vaccine development. Where to from here?

Authors:  Ahinsa Gunatilaka; Michelle L Giles
Journal:  Hum Vaccin Immunother       Date:  2021-09-09       Impact factor: 4.526

3.  [Association of temperament type and mother's emotional state with acute respiratory infection in children].

Authors:  Q Yan; T Tao; L Wang; C Fan; W Gao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-05-20

Review 4.  COVID-19: Why does disease severity vary among individuals?

Authors:  Saeed Samadizadeh; Maha Masoudi; Mostafa Rastegar; Vahid Salimi; Mahsa Bataghva Shahbaz; Alireza Tahamtan
Journal:  Respir Med       Date:  2021-03-05       Impact factor: 4.582

5.  COVID-19 in Pediatrics: Demographic, Clinical, Laboratory, and Radiological Characteristics of Infected Patients With SARS-CoV-2.

Authors:  Maryam Najafinejad; Fatemeh Cheraghali; Bahman Aghcheli; Abdolhalim Rajabi; Leila Barati; Hamed Naziri; Mohammad Hadi Gharib; Alijan Tabarraei; Britt Nakstad; Alireza Tahamtan
Journal:  Front Pediatr       Date:  2022-01-13       Impact factor: 3.418

Review 6.  Immunopathology of RSV: An Updated Review.

Authors:  Harrison C Bergeron; Ralph A Tripp
Journal:  Viruses       Date:  2021-12-10       Impact factor: 5.048

7.  Functional variation (Q63R) in the cannabinoid CB2 receptor may affect the severity of COVID-19: a human study and molecular docking.

Authors:  Mostafa Rastegar; Saeed Samadizadeh; Mohammad Yasaghi; Abdolvahab Moradi; Alijan Tabarraei; Vahid Salimi; Alireza Tahamtan
Journal:  Arch Virol       Date:  2021-09-13       Impact factor: 2.574

Review 8.  Early-Life Lung and Gut Microbiota Development and Respiratory Syncytial Virus Infection.

Authors:  Kazuma Yagi; Nobuhiro Asai; Gary B Huffnagle; Nicholas W Lukacs; Wendy Fonseca
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 8.786

9.  High bacterial and viral load in the upper respiratory tract of children in the Democratic Republic of the Congo.

Authors:  Archippe Muhandule Birindwa; Lucia Gonzales-Siles; Rickard Nordén; Shadi Geravandi; Jeanière Tumusifu Manegabe; Lambert Morisho; Stay Saili Mushobekwa; Rune Andersson; Susann Skovbjerg
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.